醋酸乌利司他; 醋酸优力司特; CAS 126784-99-4; 杂质
中文名称:醋酸优力司特;醋酸乌利司他;(11β)-17α-(乙酰氧基)-11-[4-(二甲基氨基)苯基]-19-去甲孕甾-4,9-二烯-3,20-二酮;CDB2914
英文名称:Ulipristal acetate; 17alpha-Acetoxy-11beta-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione; CDB2914
CAS 号:126784-99-4
含量标准:99% HPLC
其他相关:1. 醋酸优力司特杂质;醋酸乌利司他杂质;杂质1,2,3,4,5
2. 我司已提交专利申请《醋酸乌利司他关键中间体3,20-双(亚乙二氧基)-19-去甲孕甾-5(10)9(11)二烯-17-醇的新合成方法》,发明专利申请号:201110389309.0。
醋酸优力司特中间体; 醋酸乌利司他中间体; CAS 54201-84-2
中文名称:3,20-双(亚乙二氧基)-19-去甲孕甾-5(10)9(11)二烯-17-醇
英文名称:3, 20-Bis(ethylenedioxy)-19-norpregna-5(10),9(11)-dien-17-ol
CAS 号: 54201-84-2
含量标准:98% HPLC
其他相关:我司已提交专利申请《醋酸乌利司他关键中间体3,20-双(亚乙二氧基)-19-去甲孕甾-5(10)9(11)二烯-17-醇的新合成方法》,发明专利申请号:201110389309.0。
醋酸优力司特中间体; 醋酸乌利司他中间体; CAS 14340-01-3
中文名称:孕诺二烯醇
英文名称:Gestadienol
CAS 号:14340-01-3
含量标准:98% HPLC
醋酸优力司特中间体; 醋酸乌利司他中间体; CAS 42982-49-0
中文名称:3-(亚乙二氧基)-17α-羟基-19-去甲孕甾-5(10),9(11)-二烯-20-酮
英文名称:3-(Ethylene-dioxy)-17alpha-hydroxy-19-norpregna-5(10),9(11)-diene-20-one
CAS 号:42982-49-0
含量标准:98% HPLC
醋酸优力司特中间体; 醋酸乌利司他中间体; CAS 126690-41-3
中文名称:3,3,20,20-双(亚乙二氧基)- 5α,17α-二羟基-11β-[4-(N,N-二甲基氨基)-苯基]-19-去甲孕甾-9(11)-烯
英文名称:3,3,3,20,20-Bis(ethylene-dioxy) -5alpha,17alpha-dihydroxy-11beta-[4-(N, N-dimethylamino)-phenyl]-19-norpregna-9(11)-ene
CAS 号:126690-41-3
含量标准:98% HPLC
醋酸优力司特中间体; 醋酸乌利司他中间体; CAS 159811-51-5
中文名称:11β-[4-(N,N-二甲基氨基)-苯基]-17α-羟基-19-去甲孕甾-4,9-二烯-3,20-二酮
英文名称:11beta-[4-(N,N-dimethylamino)-phenyl]-17alpha-hydroxy-19-norpregna-4,9-diene-3,20-dione
CAS 号: 159811-51-5
含量标准:98% HPLC
醋酸优力司特中间体; 醋酸乌利司他中间体; CAS 33300-19-5
中文名称:3-双(亚乙二氧基)-17α-羟基-17β-腈基-19-去甲孕甾-5(10),9(11)-二烯-3,20–二酮
英文名称:Cyclic-3-(1,2-ethanediylacetal)-17beta-cyano-17alpha-hydroxy-estra-5(10),9(11)-dien-3-one
CAS 号:33300-19-5
含量标准:98% HPLC
关键字: CDB2914;乌利司他;优力司特;126784-99-4;54201-84-2;醋酸乌利司他;醋酸优力司特
We are offering three key services for new drug application,
a. Mature(repeatable) pilot process with independent intellectual property rights;
b. High purity sample designed for pharm companies;
c. Impurity study.
Our main products are Ulipristal acetate intermediates &impurities; Alogliptin benzoate intermediates, impurities &metabolin; Ezetimibe intermediates &impurities; Abiraterone Acetate; Dienogest; Tenofovir disoproxil fumarate & its intermediates; Bortezomib; Cabazitaxel; Lacosamide intermediates; Minodronic acid.